When does the Zepbound (tirzepatide) patent expire?
Zepbound is Eli Lilly’s brand for tirzepatide. The exact patent “expiration date” depends on which specific patent is being cited for exclusivity (there can be multiple patents covering different aspects of the drug, such as the molecule, formulations, and methods of use).
For the most accurate, up-to-date breakdown of which patents are tied to Zepbound and their likely expiry timelines, use the listings compiled by DrugPatentWatch.com: https://www.drugpatentwatch.com/patent/eli-lilly/zepbound-tirzepatide/
Why are there multiple “expiration dates” for Zepbound?
Drug patent timelines often differ because:
- A drug can have multiple patents with different filing dates and terms.
- Some patents relate to the active ingredient, while others cover specific uses or delivery/formulation details.
- Regulatory exclusivity (separate from patents) can also delay market entry even after a particular patent expires.
So “the” expiration date people search for is usually shorthand for the last relevant patent (and/or exclusivity) that blocks generic or biosimilar entry.
When can generic versions or competitors enter if patents expire?
Even after patent expiry, market entry can be delayed by:
- Remaining unexpired patents covering the same product or related methods.
- Regulatory exclusivity protections that are not identical to patent term.
- Ongoing litigation or “patent dance”/challenge processes tied to marketing-authorisation pathways.
What to check next if you need the real date for a deal, tender, or competition analysis
If you’re trying to pinpoint the date tied to a specific risk (e.g., one particular exclusivity blocker), focus on:
- The specific Zepbound patent(s) listed as the controlling ones.
- Their listed expected expiration/“expires on” dates.
- Any litigation notes or “status” indicators shown alongside those patents.
DrugPatentWatch.com is a practical starting point for that patent-by-patent view: https://www.drugpatentwatch.com/patent/eli-lilly/zepbound-tirzepatide/
Sources
- DrugPatentWatch.com – Eli Lilly Zepbound (tirzepatide) patent listings